Chenqi Xu is now a principle investigator at Shanghai Institute of Biochemistry and Cell Biology (SIBCB), Chinese Academy of Sciences. He completed PhD training in protein chemistry with Dr. Chengwu Chi in 2004 at SIBCB, and then received postdoctoral training in immunology with Dr. Kai Wucherpfennig at Harvard Medical School. In 2009, he moved back to SIBCB to start his independent program focusing on T cell signaling and metabolism. The Xu lab has developed cutting-edge biochemical and biophysical tools to study immunoreceptor signaling and engineering. On the other hand, he is interested in the fundamental functions of membrane lipids in T cell biology and have demonstrated the application potential of cholesterol-based immunotherapy. His works have been published in Nature, Cell and other prestigious journals, and selected as Top 10 Science Breakthroughs in China. He has received many awards, including the 2022 Chinese Biological Investigators Society Young Investigator Award and the 2023 Xplorer Prize.